MONTEREY, Calif.--(BUSINESS WIRE)--Vybion announces the issue by the USPTO of Patent No. 9932394 entitled, “Single Chain Intrabodies that Alter Huntingtin Mutant Degradation”. Issued claims cover composition of matter as well as both the Huntingtin and Tau protein targets with the potential for treatment of both Huntington’s and Alzheimer’s diseases. A continuation on the remaining methods claims has been filed. This patent application is also pending in multiple jurisdictions in Europe and Asia.
“We are pleased with the notification from the patent office of the first of several patents we expect to issue for the use of Intrabody INT41, delivered by AAV, for the treatment of neurodegenerative diseases. Our current focus is on Huntington’s disease where we are planning IND enabling studies,” said Lee Henderson, Vybion CEO. Vybion scientists have previously published findings demonstrating that INT41 accelerates degradation of the toxic gain of function fragment of the mutant huntingtin protein thereby decreasing gene dysregulation and perinuclear aggregation caused by this huntingtin protein degradation fragment (http://dx.doi.org/10.1155/2016/7120753).
About Vybion, Inc. Vybion is a development stage Company with proprietary technologies for Intrabody development currently pursuing strategies to treat neurodegenerative diseases such as Huntington's, SBMA and SCA1, 3, 7 and Alzheimer’s.